Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGiulia RivoliOspedale Policlinico San MartinoCGCarmela GurrieriUniversity of PaduaCPCristina PapayannidisIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

Discussion

Loading...

Member takes

Implication

This analysis reports the effectiveness of asciminib in treating Ph+ ALL and LBC-CML, suggesting improved outcomes with combination therapy.

Key Points

  • Asciminib indicates significant efficacy for relapsed Ph+ ALL and LBC-CML, with promising results in combination therapy.
  • Among patients, a 62.9% estimated one-year overall survival was noted, highlighting potent therapeutic effects of asciminib.
  • Retrospective evaluation utilized patient data from an Italian compassionate use program for asciminib in Ph+ leukemia.
  • Asciminib's potential increases with combination therapy, pointing to enhanced treatment strategies for relapsed cases.

Cite This Study

Rivoli et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de75https://doi.org/10.1182/blood-2025-1572
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase2025
  2. 2Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  3. 3Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis2025
  4. 4Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results2026
  5. 5A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase2025